Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
South Africa
0
Weekly News Recap #Phispers
1. Bms 907351
2. Bms-907351
3. Bms907351
4. Cabozantinib
5. Cometriq
6. Xl 184
7. Xl-184
8. Xl184 Cpd
1. 1140909-48-3
2. Cabozantinib Malate
3. Cabozantinib (s)-malate
4. Cabometyx
5. Cabozantinib Malate (xl184)
6. Xl184
7. Cabozantinib (s-malate)
8. Cometriq
9. Cabozantinib S-malate [usan]
10. Dr7st46x58
11. Bms907351
12. Chebi:72319
13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
14. Cabometyx (tn)
15. Cometriq (tn)
16. Cabozantinib Malate (jan)
17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid
18. Cabozantinib S-malate (usan)
19. Cabozantinib Malate [jan]
20. Unii-dr7st46x58
21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
23. Xl184 Malate
24. Cabozantinib L-malate
25. Bms907351 Malate
26. Xl184(cabozantinib Malate)
27. Mls006010951
28. Chembl2103868
29. Dtxsid60915949
30. Ex-a2819
31. Mfcd20923480
32. S4001
33. 1140909-48-3 (malate)
34. Akos025401945
35. Cabozantinib S-malate [who-dd]
36. Ccg-270301
37. Cs-0201
38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor
39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
40. Ac-27471
41. As-75255
42. Hy-12044
43. Smr004702755
44. Cabozantinib S-malate [orange Book]
45. Sw218093-2
46. D10095
47. Q27139901
48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)
52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt
53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)
54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate
Molecular Weight | 635.6 g/mol |
---|---|
Molecular Formula | C32H30FN3O10 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 11 |
Exact Mass | 635.19152232 g/mol |
Monoisotopic Mass | 635.19152232 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 46 |
Formal Charge | 0 |
Complexity | 924 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
* Renal Cell Carcinoma (RCC):
Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):
- in treatment-nave adults with intermediate or poor risk,
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
* Hepatocellular Carcinoma (HCC):
Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
L01EX07
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39757
Submission : 2024-03-22
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38207
Submission : 2023-03-31
Status : Active
Type : II
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39785
Submission : 2024-03-26
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39141
Submission : 2023-12-01
Status : Active
Type : II
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39274
Submission : 2023-12-29
Status : Active
Type : II
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-03-23
Pay. Date : 2022-02-28
DMF Number : 36509
Submission : 2022-02-28
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-12-17
Pay. Date : 2019-10-11
DMF Number : 34201
Submission : 2019-11-06
Status : Active
Type : II
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39785
Submission : 2024-03-26
Status : Active
Type : II
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39757
Submission : 2024-03-22
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39141
Submission : 2023-12-01
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38207
Submission : 2023-03-31
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39274
Submission : 2023-12-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-12-06
Pay. Date : 2023-03-08
DMF Number : 38057
Submission : 2023-09-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-08
Pay. Date : 2017-05-22
DMF Number : 31522
Submission : 2017-03-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-25
Pay. Date : 2019-04-22
DMF Number : 33137
Submission : 2018-09-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-03-23
Pay. Date : 2022-02-28
DMF Number : 36509
Submission : 2022-02-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-12-17
Pay. Date : 2019-10-11
DMF Number : 34201
Submission : 2019-11-06
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
Date of Issue : 2019-08-05
Valid Till : 2022-05-05
Written Confirmation Number : WC-0349A3
Address of the Firm : Unit-||, Sy. No. 50, Kardanur Village, Patti/Post Patancheru Mandal,Medak Distri...
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
About the Company : Granules is a vertically integrated fast-growing Pharmaceutical company headquartered in Hyderabad with best-in-class facilities & a commitment to operational excellence, quality, ...
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
About the Company : Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is de...
About the Company : Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over ...
About the Company : Xieli is an EU GMP\ Japan GMP\ Chinese GMP certified manufacturer of Botanical derivative APIs and Oncology APIs from China.A leading producer of Rutin, Troxerutin, Diosmin, Artemi...
About the Company : We are a world class innovation driven specialty pharmaceutical company with integrated Research, Development, Manufacturing and Marketing of Quality affordable medicines for a Hea...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 60MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Olpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.
Regulatory Info : Dossier Readiness: Q1 2026
Registration Country : Latvia
Brand Name :
Dosage Form : Tablet
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Dossier Readiness: Q1 2026
Registration Country : Latvia
Regulatory Info :
Registration Country : USA
Brand Name : CABOZANTINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number : 215942
Regulatory Info :
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : COMETRIQ
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 20MG BASE
Packaging :
Approval Date : 2012-11-29
Application Number : 203756
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form :
Dosage Strength :
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Australia
Brand Name : Cabometyx
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Cabometyx
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
30 Nov 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/fda-oncology-advisory-committee-weigh-exelixis-cabometyxs-worth-neuroendocrine-tumors
26 Nov 2024
// BUSINESSWIRE
16 Oct 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/exelixis-stock-rises-key-drug-cabometyx-withstands-patent-challenges
17 Sep 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/despite-survival-miss-exelixis-presses-fda-prostate-cancer-filing-ipsen-scraps-eu-plan
16 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/16/2946663/0/en/Final-results-from-CABINET-Phase-III-trial-reinforce-efficacy-benefits-of-Cabometyx-in-advanced-neuroendocrine-tumors.html
16 Sep 2024
// BUSINESSWIRE
Global Sales Information
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 349
2019 Revenue in Millions : 293
Growth (%) : 19
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 390
2020 Revenue in Millions : 349
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 481
2021 Revenue in Millions : 390
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 577
2022 Revenue in Millions : 481
Growth (%) : 19
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 59
2021 Revenue in Millions : 54
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 56
2022 Revenue in Millions : 60
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 7
2015 Revenue in Millions : Not Reported
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 64
2016 Revenue in Millions : 9
Growth (%) : 618
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 167
2017 Revenue in Millions : 58
Growth (%) : 187%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 264
2018 Revenue in Millions : 162
Growth (%) : 63
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2032-02-10
US Patent Number : 12128039
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208692
Patent Use Code : U-2488
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-02-10
Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-3225
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-01-15
Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-3225
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-01-15
Patent Expiration Date : 2030-10-08
US Patent Number : 8877776
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203756
Patent Use Code : U-1617
Delist Requested :
Patent Use Description : METHOD OF TREATING MED...
Patent Expiration Date : 2030-10-08
Patent Expiration Date : 2024-09-24
US Patent Number : 8497284
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-2488
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2024-09-24
Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-1220
Delist Requested :
Patent Use Description : TREATMENT OF RENAL CEL...
Patent Expiration Date : 2030-01-15
Patent Expiration Date : 2030-01-15
US Patent Number : 11091439
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 208692
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-01-15
Patent Expiration Date : 2030-10-08
US Patent Number : 8877776
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203756
Patent Use Code : U-1617
Delist Requested :
Patent Use Description : METHOD OF TREATING MED...
Patent Expiration Date : 2030-10-08
Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-1480
Delist Requested :
Patent Use Description : TREATMENT OF ADVANCED ...
Patent Expiration Date : 2030-01-15
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cabozantinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib, including repackagers and relabelers. The FDA regulates Cabozantinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabozantinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabozantinib supplier is an individual or a company that provides Cabozantinib active pharmaceutical ingredient (API) or Cabozantinib finished formulations upon request. The Cabozantinib suppliers may include Cabozantinib API manufacturers, exporters, distributors and traders.
click here to find a list of Cabozantinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cabozantinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib DMFs exist exist since differing nations have different regulations, such as Cabozantinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cabozantinib DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib USDMF includes data on Cabozantinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cabozantinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cabozantinib Drug Master File in Korea (Cabozantinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib. The MFDS reviews the Cabozantinib KDMF as part of the drug registration process and uses the information provided in the Cabozantinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cabozantinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cabozantinib suppliers with KDMF on PharmaCompass.
A Cabozantinib written confirmation (Cabozantinib WC) is an official document issued by a regulatory agency to a Cabozantinib manufacturer, verifying that the manufacturing facility of a Cabozantinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib APIs or Cabozantinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Cabozantinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabozantinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabozantinib suppliers with NDC on PharmaCompass.
Cabozantinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cabozantinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib GMP manufacturer or Cabozantinib GMP API supplier for your needs.
A Cabozantinib CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib's compliance with Cabozantinib specifications and serves as a tool for batch-level quality control.
Cabozantinib CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cabozantinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib EP), Cabozantinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib USP).
LOOKING FOR A SUPPLIER?